Xenon Pharmaceuticals (XENE) Operating Margin (2013 - 2025)

Xenon Pharmaceuticals (XENE) has 10 years of Operating Margin data on file, last reported at 969.84% in Q1 2025.

• Operating Margin for Q1 2025 came in at 969.84%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 4974.27% (changed N/A YoY), and the FY2025 annual result was 4974.27%, changed N/A from the prior year.
• Operating Margin advanced to 969.84% in Q1 2025 per XENE's latest filing, from 28884.85% in the prior quarter.
• Over five years, Operating Margin peaked at 879.18% in Q4 2021 and troughed at 28884.85% in Q3 2022.
• A 3-year average of 4569.86% and a median of 669.17% in 2021 frame the typical range for Operating Margin.
• The sharpest annual moves came in 2021 and 2022: Operating Margin soared 67487 bps in 2021, then slumped 2853823 bps in 2022.
• A 3-year view of Operating Margin shows it stood at 879.18% in 2021, then tumbled by 3385 bps to 28884.85% in 2022, then surged by 97 bps to 969.84% in 2025.
• Business Quant data shows XENE's Operating Margin at 969.84% in Q1 2025, 28884.85% in Q3 2022, and 5655.78% in Q2 2022.